Astrazeneca’s Farxiga (dapagliflozin) was initially approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) in January 2014. The approval of Farxiga for the treatment of HFrEF is based on the positive results of the Phase III DAPA-HF trial. The efficacy of Farxiga in HFrEF was independent of whether patients had comorbid T2D. Learn more about the importance of Farxiga in the treatment of HFrEF & HFpEF, from DRG expert, Dominika Rudnicka-Noulin.


Key Disruptors in The Multiple Myeloma Landscape: 2020 and Beyond

View Now